Development of a novel platform of virus-like particle (VLP)-based vaccine against COVID-19 by exposing epitopes: an immunoinformatics approach.
COVID-19
epitope prediction
immunoinformatics
severe acute respiratory syndrome coronavirus 2
vaccine
virus-like particles
Journal
New microbes and new infections
ISSN: 2052-2975
Titre abrégé: New Microbes New Infect
Pays: England
ID NLM: 101624750
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
15
06
2020
revised:
07
10
2020
accepted:
08
10
2020
pubmed:
20
10
2020
medline:
20
10
2020
entrez:
19
10
2020
Statut:
ppublish
Résumé
The emergence of a rapidly spreading and highly infectious coronavirus disease 2019 (COVID-19) outbreak by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused a global pandemic with unprecedented social and economic dimensions. Therefore, the development of effective strategies is urgent to control the COVID-19 outbreak. According to recent investigations, cell entry of coronaviruses relies on binding of the viral spike glycoprotein to the host cellular receptors. Therefore, the present study aimed to predict immunogenic epitopes in silico by analysing the spike protein. In parallel, by screening the immunogenic SARS-CoV-2 spike-derived epitopes provided in the literature, we chose a set of epitopes that we believed would induce immunogenic response. Next, provided with the epitopes selected by using both approaches, we performed immunoinformatic analysis that mapped identically to the antigen regions and antigenic properties. Finally, after selecting a screened set of epitopes, we designed a novel virus-like particle vaccine optimized to be produced in plants by using molecular farming biotechnology techniques. Our assay may be used as a starting point for guiding experimental efforts towards the development of a vaccine against SARS-CoV-2.
Identifiants
pubmed: 33072338
doi: 10.1016/j.nmni.2020.100786
pii: S2052-2975(20)30138-4
pmc: PMC7556220
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100786Informations de copyright
© 2020 Published by Elsevier Ltd.
Références
Inform Med Unlocked. 2020;20:100394
pubmed: 32835079
Adv Drug Deliv Rev. 2015 Oct 1;93:42-55
pubmed: 25451136
Bioinformatics. 2019 Sep 1;35(17):3020-3027
pubmed: 30657872
Front Plant Sci. 2019 Apr 16;10:455
pubmed: 31057572
J Med Virol. 2020 Nov;92(11):2260-2262
pubmed: 32462717
Acta Biochim Pol. 2014;61(3):531-9
pubmed: 25273564
Cell Host Microbe. 2020 Apr 8;27(4):671-680.e2
pubmed: 32183941
Nucleic Acids Res. 2019 Jan 8;47(D1):D339-D343
pubmed: 30357391
Hum Vaccin Immunother. 2013 Jan;9(1):26-49
pubmed: 22995837
Nature. 2004 Apr 1;428(6982):561-4
pubmed: 15024391
Cell. 2020 May 14;181(4):894-904.e9
pubmed: 32275855
Emerg Microbes Infect. 2020 Dec;9(1):382-385
pubmed: 32065055
Immunol Res. 2014 Aug;59(1-3):118-28
pubmed: 24845462
Cell Res. 2020 Apr;30(4):343-355
pubmed: 32231345
Bioinform Biol Insights. 2018 May 14;12:1177932218755337
pubmed: 29780242
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
N Engl J Med. 2012 Nov 8;367(19):1814-20
pubmed: 23075143
BMC Biotechnol. 2017 Nov 10;17(1):79
pubmed: 29126399
Infect Genet Evol. 2020 Nov;85:104556
pubmed: 32937193
Viruses. 2020 Feb 25;12(3):
pubmed: 32106567
J Med Virol. 2020 Nov;92(11):2314-2315
pubmed: 32391920
Science. 2020 May 8;368(6491):630-633
pubmed: 32245784
Cent Eur J Immunol. 2018;43(2):194-203
pubmed: 30135633
Protein Cell. 2020 Apr;11(4):235-238
pubmed: 32088858
Cell. 2020 Oct 29;183(3):730-738.e13
pubmed: 32979942
Expert Opin Biol Ther. 2020 Jun;20(6):545-548
pubmed: 32250170
Expert Rev Vaccines. 2018 Aug;17(8):677-686
pubmed: 30058403
J Med Virol. 2020 Jun;92(6):618-631
pubmed: 32108359
Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6641-6
pubmed: 15096611
Int J Biol Sci. 2020 Mar 15;16(10):1678-1685
pubmed: 32226285
Nat Commun. 2020 Mar 27;11(1):1620
pubmed: 32221306
Cell Mol Immunol. 2020 May;17(5):536-538
pubmed: 32132669
Intervirology. 2013;56(3):141-65
pubmed: 23594863
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651